Drug Trial Radar · NCT00224146
Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
Last checked: Nov 20, 2026Latest source record: Nov 30, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,878
Actual
Start
May 2004
Primary completion
May 2005
Study completion May 2005
Sponsor
- Lead sponsor
- Watson PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)
Conditions
- Overactive Bladder
- Urinary Incontinence
- Quality of Life
Interventions
oxybutynin transdermal delivery system (Oxytrol(r))Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in health-related quality of life
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Mobile, Alabama
Site not named
Tucson, Arizona
Site not named
Torrance, California
Site not named
Rocky Hill, Connecticut
Site not named
Valdosta, Georgia
Site not named
Gretna, Louisiana
Site not named
Bloomfield Hills, Michigan
Site not named
Poughkeepsie, New York
Site not named
Winston-Salem, North Carolina
Site not named
Tomball, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.